Advanced in Xeroderma Pigmentosum

Marc Espie

Paris, FR 
Advanced in Xeroderma Pigmentosum
Paris, FR 
OverviewLocationsClinical Research

Overview

Marc Espie practices in Paris, France. Mr. Espie is rated as an Advanced expert by MediFind in the treatment of Xeroderma Pigmentosum. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Mastectomy, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 142 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Xeroderma Pigmentosum.

Gender
Male

Locations

Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Enrollment Status: Completed
Publish Date: November 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France: the FEERIC Study
FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France: the FEERIC Study
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Other
Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.
Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.
Enrollment Status: Unknown
Publish Date: April 09, 2018
Intervention Type: Biological
Study Drug: Circulating tumor cells
Study Phase: Phase 3
A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Enrollment Status: Terminated
Publish Date: May 24, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

142 Total Publications

Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score Analysis.
Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score Analysis.
Journal: Cancer medicine
Published: March 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Espie's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile